Work

A phase I and pharmacokinetic study of multiple schedules of ganetespib (STA-9090), a heat shock protein 90 inhibitor, in combination with docetaxel for subjects with advanced solid tumor malignancies.

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.3094

Authors: John S. Kauh, R Donald Harvey, Taofeek Kunle Owonikoko, Bassel F. El-Rayes, Dong Moon Shin, Sujatha Murali, Colleen Margaret Lewis, Michael D. Karol, Florentina Teofilovici, Yuhong Du, Haian Fu, Fadlo Raja Khuri, Suresh S. Ramalingam

Institutions: Emory University, Winship Cancer Institute, Synta Pharmaceuticals (United States)

Language: English

Topic: Heat shock proteins research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2602869164

Cites:

Cited by: 10

Related to: 10